Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology drug development Drug prices research pharma

	Profile	Recent Articles on Subject
1	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	AstraZeneca offers some reassurance on China challenges - about 2 months ago AstraZeneca falls on reports of Chinese probe - 5 months ago
2	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	How Astellas juggles the moving parts of cancer precision medicine development - 4 months ago How Alexion markets a rare disease drug by ‘starting with the end in mind’ - 4 months ago How AZ’s respiratory wins are ramping up for a bigger prize in COPD - 5 months ago A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill - 9 months ago AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets - 11 months ago J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff - about 1 year ago The head of AstraZeneca’s new digital health spinoff on how the pharma is leveraging tech - over 1 year ago
3	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Despite probe, China reimbursing AstraZeneca drug - 4 months ago A win for Apellis, a setback for Astellas - 5 months ago The biotech news roundup to start your week - 5 months ago STAT+: Potential competition for RSV prophylactic Beyfortus - 6 months ago Lilly has more positive data on its weekly insulin - 7 months ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: AstraZeneca says China has detained a senior executive - 5 months ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 5 months ago STAT+: Pharmalittle: We’re reading about FDA oversight of shortages, AstraZeneca threats, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 7 months ago STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more - 7 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more - 7 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more - 12 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more - about 1 year ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - over 1 year ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - over 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - over 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - over 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - over 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - over 1 year ago
5	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - 6 months ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	News from ESMO: An AstraZeneca win in bladder cancer, and more - 7 months ago STAT+: As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal - about 1 year ago STAT+: AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal - about 1 year ago STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug - about 1 year ago STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions - over 1 year ago STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca - over 1 year ago STAT+: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial - over 1 year ago
7	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 7 months ago
8	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	AstraZeneca Caps Inhaled Respiratory Portfolio at $35 For Eligible Patients With Asthma, COPD - about 1 year ago AstraZeneca to Initiate Trial for Triple-Combination Inhaled Therapy for Chronic Obstructive Pulmonary Disease - about 1 year ago
9	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation - about 1 year ago
10	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Behind a big-name rare disease biotech, an exec draws from personal experience - about 1 year ago Astellas’ science chief on the leap into new technologies - about 1 year ago Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - about 1 year ago

Journalists covering Astellas